产品名称：Gontivimab
中文名称：格替伟单抗
产品别称：ALX-0171、VR-465
靶点：RSV glycoprotein F [Respiratory syncytial virus]
体外实验：Gontivimab (0-100000 nM) 显示出抗病毒活性，对 RSV-A、RSV-B 18537 菌株的 IC50 分别为 0.1、0.4 nM[1]。
体内实验：Gontivimab （1-68 mg/kg鼻内给药或0.3-2mg/kg雾化） 有效降低棉花鼠鼻腔和肺部的 RSV滴度[1]。
Animal Model: | Cotton Rats (RSV Tracy) |
Dosage: | 1-68 mg/kg by inhalation or 0.3-2mg/kg by nebulization |
Administration: | inhalation once (day 2 or day 3）ortwice (day 2 and day 3)；nebulization 1 h before RSV Tracy challenge
|
Result: | Resulted in significant RSV titers reductions both in nasal and lung. As nebulization has been shown to result in fast and efficient drug delivery to the principal site of RSV infection. |
参考文献：1.Detalle L, Stohr T, Palomo C, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2015;60(1):6-13. Published 2015 Oct 5. doi:10.1128/AAC.01802-15
仅供科研使用
